Abstract: Described herein is a method of treating malignant tumors or other cancerous conditions with thiazolidine-4-carboxylic acid, or pharmaceutically acceptable salts thereof, to arrest or retard the growth of the tumor. These agents induce reverse transformation in the tumor cells and restore to the cells the property of contact inhibition. A novel process for the preparation of the salts of thiazolidine-4-carboxylic acid is also described.

Abstract: The Specification discloses:1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.

Abstract: The Specification discloses:1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.

Abstract: Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.

Abstract: Described herein are compositions obtained in accordance with the procedure which comprises placing in a pressure vessel a quantity of material comprising animal tissue selected from the group consisting of fresh human placenta or other animal tissues, enclosing and sealing the pressure vessel, maintaining the temperature within the vessel between about 5.degree. C. and less than 60.degree. C. and the pressure greater than about 15 psig and less than about 45 psig over a period from about 2 weeks to about 1 year, opening the vessel at the conclusion of that period and recovering and sterilizing a liquid portion of the semiliquid contents of the vessel. Preferably, the material is maintained in the vessel at a temperature from about 35.degree. C. to about 55.degree. C. and a pressure from about 23 psig to about 37 psig for a period from about 3 to about 4 months. The recovered, sterilized portion can be immediately employed or lyophilized and subsequently reconstituted with, e.g.

Abstract: N.sup.6 -Carbamoyl and -carbonyl analogs of adenosine 3',5'-cyclic phosphate (cAMP) are prepared and variously demonstrated to exhibit kinase, adrenal steroidogenisis and lipolysis activation superior to cAMP, inhibit phosphodiesterase, and found to increase cardiac output or, in particular cases, to lower blood pressure.

Abstract: Antiviral 1-(G)-1,2,4-triazole carboxamides, thiocarboxamides and carboxamidines wherein G is an acid labile hydrocarbon moiety, e.g., 1-(.alpha.-alkoxyalkyl), are prepared by, e.g., the acid-catalyzed addition reaction of appropriately substituted 1,2,4-triazole and an .alpha.,.beta.-unsaturated ether.

Abstract: Phosphate and carboxylic acid esters of 1-(.beta.-D-ribofuranosyl)-1,2,4-triazoles are prepared by a variety of methods and their antiviral activity reported.

Abstract: A 5-hydroxy-1,2,3-triazole-4-carboxamide nucleoside, related to the C-nucleoside pyrazomycin, is facilely synthesized by condensation of acyl-blocked ribofuranose with trimethylsilylated 5-hydroxy-1,2,3-triazole-4-carboxamide or, alternatively, by cycloaddition of suitably blocked .beta.-D-ribofuranosyl azide and the anion of ethyl malonamate, and demonstrated to exhibit antiviral properties. The triazole precursor of the former route, as well as certain of its novel salts, are also disclosed as potential antiviral agents.

Abstract: Described herein are novel 6-alkylthio and 6-arylalkylthio purine 3',5' cyclic nucleotides variously exhibiting adenyl cyclase and (in animal studies) tumor inhibitory properties, interferon potentiation, antiviral activity, and the ability to activate adenosine 3',5'-cyclic phosphate-dependent protein kinase while enjoying resistance to phosphodiesterase hydrolysis superior to that of its naturally occuring analog. The compounds are obtained by alkylation of the corresponding 6-thio nucleotide, which is in turn provided by a novel synthetic route.